Women Receive Greater Benefit from Warfarin Therapy in AF

FEBRUARY 01, 2006
Anna D. Garrett, PharmD, BCPS, CPP

Results of previous studies regarding gender differences and the risk of thromboembolism (TE) in the setting of atrial fibrillation (AF) have been conflicting. A recent study by Fang et al, published in Circulation, however, suggests that women may have a greater risk of TE than men. The investigators conducted a study of over 13,000 patients with AF and recorded data on patients' clinical characteristics and occurrences of hospitalizations for ischemic stroke, hemorrhagic events, and peripheral embolism. An extensive analysis of the data suggested that the rate of TE in women was twice as high in those not taking warfarin. Warfarin use was associated with significantly lower event rates in both sexes. Annual rates of major hemorrhage were similar for men and women. The authors concluded that women are at higher risk for AF-related events off warfarin and that female sex should be considered as an independent risk factor for TE in the setting of AF.

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.




SHARE THIS SHARE THIS
0
 

In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine

Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.


 

 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.